Codiak BioSciences (Codiak BioSciences) FCF Margin % : -36,139.29% (As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Codiak BioSciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Codiak BioSciences's Free Cash Flow for the three months ended in Sep. 2022 was $-10.12 Mil. Codiak BioSciences's Revenue for the three months ended in Sep. 2022 was $0.03 Mil. Therefore, Codiak BioSciences's FCF Margin % for the quarter that ended in Sep. 2022 was -36,139.29%.

As of today, Codiak BioSciences's current FCF Yield % is 0.00%.

The historical rank and industry rank for Codiak BioSciences's FCF Margin % or its related term are showing as below:

CDAKQ' s FCF Margin % Range Over the Past 10 Years
Min: -201.86 Med: 0 Max: 0
Current: -201.86

CDAKQ's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -143.92 vs CDAKQ: -201.86

Codiak BioSciences FCF Margin % Historical Data

The historical data trend for Codiak BioSciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Codiak BioSciences FCF Margin % Chart

Codiak BioSciences Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

FCF Margin %

-3,138.92

-2,895.81

-337.43

Codiak BioSciences Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
FCF Margin %	Get a 7-Day Free Trial										-1,369.92	-283.93	-165.56	-112.35	-36,139.29

Competitive Comparison of Codiak BioSciences's FCF Margin %

For the Biotechnology subindustry, Codiak BioSciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Codiak BioSciences's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Codiak BioSciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Codiak BioSciences's FCF Margin % falls into.

Codiak BioSciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Codiak BioSciences's FCF Margin for the fiscal year that ended in Dec. 2021 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2021 )	/	Revenue (A: Dec. 2021 )
	=	-77.389	/	22.935
	=	-337.43 %

Codiak BioSciences's FCF Margin for the quarter that ended in Sep. 2022 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2022 )	/	Revenue (Q: Sep. 2022 )
	=	-10.119	/	0.028
	=	-36,139.29 %

Codiak BioSciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of Codiak BioSciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Codiak BioSciences (Codiak BioSciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codiak BioSciences Inc (OTCPK:CDAKQ) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

35 Cambridge Park Drive, Suite 500, Cambridge, MA, USA, 02140

Website

https://www.codiakbio.com

Codiak BioSciences Inc is a development-stage biopharmaceutical company focused on the development of exosome-based therapeutics for the treatment of a wide spectrum of diseases with high unmet medical need. The company have utilized engEx Platform to generate a pipeline of engineered exosomes, aimed at treating a broad range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease, infectious disease and rare disease.

Executives

Yalonda Howze	officer: See Remarks	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Sriram Sathyanarayanan	officer: Chief Scientific Officer	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Nicole Barna	officer: See Remarks	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Douglas E Williams	director, officer: President & CEO	C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Linda Bain	officer: Chief Financial Officer	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Konstantin Konstantinov	officer: See Remarks	C/O CODIAK BIOSCIENCES, INC., 500 TECHNOLOGY SQUARE, 9TH FLOOR, CAMBRIDGE MA 02139
Arch Venture Fund Viii Overage, L.p.	10 percent owner	C/O ARCH VENTURE PARTNERS VIII, LLC, 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
David J Mauro	officer: Chief Medical Officer	36 TERRELL DRIVE, WASHINGTON CROSS PA 18977
Arundathy N. Pandite	director	1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Benny Sorensen	officer: See Remarks	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Anne-virginie Eggimann	director	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Jennifer J. Wheler	officer: Chief Medical Officer	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Briggs Morrison	director	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Alaska Permanent Fund Corp	10 percent owner	801 WEST 10TH STREET, SUITE 302, JUNEAU AK 99801
Flagship Ventures Fund V, L.p.	10 percent owner	ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142